Log in to search using one of your social media accounts:

 

Type 2 Diabetes Drug Improves Glycemic Control in Type 1 Diabetes (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS The type 2 diabetes drug dapagliflozin helps improve glycemic control when added to insulin therapy in patients with type 1 diabetes, according to an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news

Another SGLT2 Drug Shines as Insulin Adjunct in T1D (CME/CE)
(MedPage Today) -- Dapagliflozin lowered HbA1c in phase III trial (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 14, 2017 Category: Cardiology Source Type: news

DEPICT-1: Dapagliflozin Works in T1D With Little Ketoacidosis DEPICT-1: Dapagliflozin Works in T1D With Little Ketoacidosis
Dapagliflozin provided significant reductions in HbA1c, total daily insulin dose, and body weight in type 1 diabetes and was well tolerated, with no new safety signals, in a 24-week trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients
(University at Buffalo) A majority of patients with type 1 diabetes who were treated with dapagliflozin, a type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes and Endocrinology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news

dapagliflozin, Farxiga
Title: dapagliflozin, FarxigaCategory: MedicationsCreated: 12/1/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - August 8, 2017 Category: Endocrinology Source Type: news

Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes
Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - March 9, 2017 Category: Pharmaceuticals Source Type: news

Qtern (Dapagliflozin and Saxagliptin Tablets, for Oral Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 8, 2017 Category: Drugs & Pharmacology Source Type: news

Qtern (Dapagliflozin and Saxagliptin Tablets, for Oral Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 8, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes
After first rejecting it at the end of 2015, the FDA has now approved the AstraZeneca DPP-4 inhibitor/SGLT2 inhibitor fixed-dose combination product Qtern for type 2 diabetes in adults.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 28, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct to diet and exercise to improve glycaemic (blood sugar level) control in adults with type-2 diabetes who have inadequate control with dapagliflozin (10mg) or who are already treated with dapagliflozin and saxagliptin. (Source: World Pharma News)
Source: World Pharma News - February 28, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes
28 February 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2017 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - February 2017
FDA Approves Once-Daily Qtern Tablets for Adults with Type 2 Diabetes The U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s Qtern (dapagliflozin and saxagliptin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2017 Category: Pharmaceuticals Source Type: news

AstraZeneca announces availability of saxa / dapa FDC in UK
UK-based AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2017 Category: Pharmaceuticals Source Type: news

NICE recommends dapagliflozin for T2DM triple therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news

NICE approves extra ‘triple therapy’ drug for diabetes
Regulator recommends dapagliflozin in triple therapy Related items fromOnMedica Glycosylated haemoglobin (HbA1c) and screening for diabetes Diabetes drugs costs NHS England nearly £1bn a year Intensive treatment of type 2 diabetes with microalbuminuria reaps benefits NICE guidance delays hinder good diabetes care Diabetes prescriptions rise by a third in last five years (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 23, 2016 Category: UK Health Source Type: news

NICE looks set to back ‘triple therapy’ diabetes drug
The National Institute for Health and Care Excellence has provisionally recommended dapagliflozin for treating type 2 diabetes in “triple therapy”. (Source: Nursing Times)
Source: Nursing Times - October 7, 2016 Category: Nursing Source Type: news

First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes
Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Triple Therapy in Type 1 Diabetes Improves Glycemic Control but Carries Ketosis Risks (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Adding dapagliflozin to liraglutide and insulin in patients with type 1 diabetes lowers hemoglobin A1c levels but poses risk for ketoacidosis, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 4, 2016 Category: Primary Care Source Type: news

Triple therapy helped type 1 patients improve glycemia
NEW ORLEANS – The addition of dapagliflozin to insulin and liraglutide in patients with type 1 diabetes resulted in a significant improvement in glycemia, results from a single-center randomized... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 13, 2016 Category: Endocrinology Source Type: news

Farxiga (Dapagliflozin Film-coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 28, 2016 Category: Drugs & Pharmacology Source Type: news

Xigduo XR (Dapagliflozin and Metformin HCl Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 27, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Strengthens Warnings on Two Diabetes Drugs (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM Two drugs used to treat type 2 diabetes — canagliflozin and dapagliflozin — are associated with an increased risk for acute kidney injury, cautions the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 15, 2016 Category: Primary Care Source Type: news

Canagliflozin, Dapagliflozin Warnings Strengthened by FDACanagliflozin, Dapagliflozin Warnings Strengthened by FDA
The FDA has strengthened its drug label warnings about the risk for acute kidney injury in patients taking canagliflozin or dapagliflozin for type 2 diabetes. News Alerts (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 15, 2016 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
[6-14-2016] The U.S. Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 14, 2016 Category: Drugs & Pharmacology Source Type: news

AstraZeneca Combo for Type 2 Diabetes Gets Green Light in EUAstraZeneca Combo for Type 2 Diabetes Gets Green Light in EU
The EMA has given the green light to a fixed-dose combination of saxagliptin and dapagliflozin, the first combination of DPP-4/SGLT2 inhibitor in Europe, for the treatment of type 2 diabetes. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 27, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Dapagliflozin Plus Liraglutide and Insulin Effective in T1D (CME/CE)
(MedPage Today) -- But came with high risk of ketoacidosis, finds small study (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - May 27, 2016 Category: Journals (General) Source Type: news

ENDO: Farxiga Proves Effective in T1D, But Is it Safe? (CME/CE)
(MedPage Today) -- Risk of ketoacidosis when dapagliflozin added to liraglutide and insulin (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 5, 2016 Category: Consumer Health News Source Type: news

Sun Pharma to sell AstraZeneca's Type 2 diabetes medicine in India
Sun Pharmaceutical Industries has entered a partnership with AstraZeneca to sell the latter's Type 2 diabetes (T2D) medicine, dapagliflozin, in India. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 24, 2016 Category: Pharmaceuticals Source Type: news

Sun Pharma, AstraZeneca tie up to sell latest anti-diabetes drug Dapagliflozin
Diabetes estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 23, 2016 Category: Pharmaceuticals Source Type: news

Lau on Liraglutide: Is It Safe? AACE Video
NASHVILLE (MedPage Today) -- Exclusive AACE Video Conference Reporter coverage, with Hallway Takes from David C.W. Lau, PhD, on Liraglutide Safety; Shashank R. Joshi, MD, on the Saragliptin Trial; and Carolina Solis-Herrera, MD, on the Dapagliflozin Trial. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 18, 2015 Category: Cardiology Source Type: news

Three Diabetes Drugs Linked to Ketoacidosis, FDA Warns
(MedPage Today) -- FDA targets SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 16, 2015 Category: Cardiology Source Type: news

Dapagliflozin in Patients With Type 2 Diabetes MellitusDapagliflozin in Patients With Type 2 Diabetes Mellitus
Where does this SGLT2 inhibitor fit in type 2 diabetes therapy? Therapeutic Advances in Endocrinology and Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Sodium-Glucose Cotransporter 2 Inhibitors for T2DMSodium-Glucose Cotransporter 2 Inhibitors for T2DM
Learn about the new sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin in this overview, including their benefits, adverse effects, and potential place in therapy. Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Dapagliflozin Efficacy and Safety: A Perspective ReviewDapagliflozin Efficacy and Safety: A Perspective Review
How does short-term efficacy of this SGLT-2 inhibitor compare with other antidiabetic drugs? Therapeutic Advances in Drug Safety (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

dapagliflozin, Farxiga
Title: dapagliflozin, FarxigaCategory: MedicationsCreated: 12/1/2014 12:00:00 AMLast Editorial Review: 12/1/2014 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 1, 2014 Category: Endocrinology Source Type: news

dapagliflozin, Farxiga
Title: dapagliflozin, FarxigaCategory: MedicationsCreated: 12/1/2014 12:00:00 AMLast Editorial Review: 12/1/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 1, 2014 Category: Drugs & Pharmacology Source Type: news

Top medicine articles for November 2014
A collection of some interesting medical articles published recently:'To Burn Off Calories in This Soda, Walk 5 Miles' - new label http://buff.ly/1vzbCKHTwo new medications for IPF: Pirfenidone (Esbriet) affects scarring, Nintedanib (Ofev) is a kinase inhibitor http://buff.ly/1psam6m80% of people have at least 1 distressing symptom in a given month, yet fewer than 1 in 4 persons sees a doctor. At least one third of common symptoms do not have a clear-cut, disease-based explanation. History and physical examination alone contribute 73% to 94% of the diagnostic information. The patient's history alone yields 75% of the diagn...
Source: Clinical Cases and Images - November 17, 2014 Category: Journals (General) Tags: Health News of the Day Source Type: news

Xigduo XR (Dapagliflozin and Metformin HCl Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 7, 2014 Category: Drugs & Pharmacology Source Type: news

New Diabetes Combo Approved
(MedPage Today) -- Dapagliflozin plus metformin -- one tablet, once daily -- given FDA nod. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 3, 2014 Category: Cardiology Source Type: news

FDA OKs Xigduo XR, a New Dapagliflozin-Metformin ComboFDA OKs Xigduo XR, a New Dapagliflozin-Metformin Combo
Xigduo XR is the first diabetes drug in the United States to combine a sodium glucose cotransporter-2 inhibitor with metformin hydrochloride extended-release. FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 30, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
First U.S. approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--AstraZeneca (AZN) today announced that the U.S. Food and Drug Administration has approved on... Biopharmaceuticals, Endocrinology, FDAAstraZeneca, XIGDUO XR, dapagliflozin, metformin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2014 Category: Pharmaceuticals Source Type: news

Pilot Study Explores Dapagliflozin Use in Type 1 DiabetesPilot Study Explores Dapagliflozin Use in Type 1 Diabetes
Already approved for use in type 2 diabetes, the SGLT2 inhibitor dapagliflozin is tested in a pilot trial in patients with type 1 diabetes along with insulin therapy. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 8, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

AstraZeneca’s Forxiga receives positive advice from Scottish Medicines Consortium
AstraZeneca announced that the Scottish Medicines Consortium (SMC) has issued positive advice for use of its Forxiga, a selective and reversible inhibitor of sodium-glucose co-transporter-2, as part of a triple therapy regimen for type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 7, 2014 Category: Pharmaceuticals Source Type: news

Added benefit of the fixed combination of dapagliflozin, metformin is not proven, study finds
As was the case in dapagliflozin monotherapy, a drug manufacturer also presented no suitable data for the therapeutic indication in its dossier on the fixed combination with metformin. Dapagliflozin is approved both alone and in combination with other blood-glucose lowering drugs, including insulin. The fixed combination with metformin is an option for patients who are already taking dapagliflozin and metformin as separate tablets or for patients or who do not benefit sufficiently from the commonly used drug metformin. It can also be used together with other blood-glucose lowering drugs, including insulin, if metformin and...
Source: ScienceDaily Headlines - May 15, 2014 Category: Science Source Type: news

Added benefit of the fixed combination of dapagliflozin and metformin is not proven
(Institute for Quality and Efficiency in Health Care) As was the case in dapagliflozin monotherapy, the drug manufacturer also presented no suitable data for the therapeutic indication in its dossier on the fixed combination with metformin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2014 Category: Global & Universal Source Type: news

Top medicine articles for March 2014
A collection of some interesting medical articles published recently:1 in 10 U.S. Children Now Has ADHD, CDC Says http://buff.ly/IeqY1SLifestyle interventions effectively decrease the incidence of type 2 diabetes in high-risk patients http://buff.ly/1bSrw9jTime for another go at understanding vitamin D metabolism http://buff.ly/1hdob8fDo healthier foods cost more than less healthy options? Healthy eating costs an extra $1.50 per day - BMJ http://buff.ly/JEpi2t1% of women in a U.S. study who have become pregnant claim to have done so as virgins - BMJ/Reuters http://buff.ly/19zkHIZYou’re never too old to exercise: 98-y...
Source: Clinical Cases and Images - March 19, 2014 Category: Journals (General) Tags: Health News of the Day Source Type: news

AstraZeneca introduces combination drug Xigduo in UK for type 2 diabetes
AstraZeneca has launched its twice-daily tablet Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) in the UK to treat patients with type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 12, 2014 Category: Pharmaceuticals Source Type: news

AstraZeneca and Bristol-Myers Squibb announce EU approval for diabetes drug Xigduo
The European Commission has granted marketing authorisation to AstraZeneca and Bristol-Myers Squibb's (BMS's) Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) for the treatment of type 2 diabetes in the European … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 24, 2014 Category: Pharmaceuticals Source Type: news

First Approval for Flozin/Metformin Combo (Xigduo) in EUFirst Approval for Flozin/Metformin Combo (Xigduo) in EU
The first-ever approval of a combination product containing an SGLT2 inhibitor (dapagliflozin) together with metformin for type 2 diabetes has been approved in the EU. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 22, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Farxiga (Dapagliflozin Film-coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 22, 2014 Category: Drugs & Pharmacology Source Type: news